OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies
Delphine Planas, Isabelle Staropoli, Cyril Planchais, et al.
Pathogens and Immunity (2024) Vol. 10, Iss. 1, pp. 1-11
Open Access | Times Cited: 7
Delphine Planas, Isabelle Staropoli, Cyril Planchais, et al.
Pathogens and Immunity (2024) Vol. 10, Iss. 1, pp. 1-11
Open Access | Times Cited: 7
Showing 7 citing articles:
The Virtual Lab: AI Agents Design New SARS-CoV-2 Nanobodies with Experimental Validation
Kyle Swanson, Wesley Wu, Nash L. Bulaong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 7
Kyle Swanson, Wesley Wu, Nash L. Bulaong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 7
Neutralizing Activity and Viral Escape of Pemivibart by SARS-CoV-2 JN.1 sublineages
T Yao, Zhenghai Ma, Ke Lan, et al.
(2024)
Open Access | Times Cited: 5
T Yao, Zhenghai Ma, Ke Lan, et al.
(2024)
Open Access | Times Cited: 5
SA55 broadly neutralizes SARS-CoV-2 and robustly prevents viral escape by JN.1 sublineages
Longqing Shi, Anthony Bowen, Juan Han, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Longqing Shi, Anthony Bowen, Juan Han, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges
Daniele Focosi, David J. Sullivan, Massimo Franchini
Expert Review of Anti-infective Therapy (2025)
Closed Access
Daniele Focosi, David J. Sullivan, Massimo Franchini
Expert Review of Anti-infective Therapy (2025)
Closed Access
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial
Simone Hoffmann, Eva Schrezenmeier, Maxime Desmarets, et al.
EBioMedicine (2025) Vol. 113, pp. 105613-105613
Open Access
Simone Hoffmann, Eva Schrezenmeier, Maxime Desmarets, et al.
EBioMedicine (2025) Vol. 113, pp. 105613-105613
Open Access
Potent bivalent nanobody constructs that protect against the SARS-CoV-2 XBB variant
Peter Halfmann, Jeong Soo Lee, Nikki McArthur, et al.
npj Viruses (2025) Vol. 3, Iss. 1
Open Access
Peter Halfmann, Jeong Soo Lee, Nikki McArthur, et al.
npj Viruses (2025) Vol. 3, Iss. 1
Open Access
Structural Immunology of SARS ‐CoV ‐2
Meng Yuan, Ian A. Wilson
Immunological Reviews (2024)
Open Access | Times Cited: 1
Meng Yuan, Ian A. Wilson
Immunological Reviews (2024)
Open Access | Times Cited: 1
Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants
Fanglei Zuo, Yunlong Cao, Rui Sun, et al.
Journal of Virology (2024) Vol. 99, Iss. 1
Closed Access
Fanglei Zuo, Yunlong Cao, Rui Sun, et al.
Journal of Virology (2024) Vol. 99, Iss. 1
Closed Access
